GlassScriptPhysician profile
Marc Aaron Moore
NPI 1225185044
$4,552.85
in general payments reported to CMS, 2019-2025
26 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $382 · 2021: $230 · 2022: $739 · 2023: $886 · 2024: $825 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.78 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,366.39 | 2019-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Mallinckrodt Hospital Products INC. | $462.42 | 2022-2025 | Acthar |
| Oyster Point Pharma, INC. | $457.56 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $407.96 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $208.00 | 2019-2023 | |
| Horizon Therapeutics Plc | $191.18 | 2022-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $179.45 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $178.14 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $155.91 | 2022-2025 | |
| Allergan, INC. | $129.37 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $122.21 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $106.77 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $90.18 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $65.16 | 2021 | |
| Astellas Pharma US INC | $56.05 | 2024-2025 | Izervay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $51.78 | 2024-2025 | Oxervate |
| Amgen INC. | $49.63 | 2024-2025 | Tepezza |
| Genentech USA, INC. | $47.96 | 2024-2025 | Vabysmo |
| Eyevance Pharmaceuticals LLC | $47.36 | 2019-2020 | |
| Ocular Therapeutix, INC. | $36.05 | 2022-2023 | Dextenza |
| Ani Pharmaceuticals, INC. | $32.69 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $31.71 | 2019 | |
| Sun Pharmaceutical Industries INC. | $26.97 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rxsight INC | $18.12 | 2022 | |
| Genzyme Corporation | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.